Anthrax vaccine injectable - DynPort

Drug Profile

Anthrax vaccine injectable - DynPort

Alternative Names: Bacillus anthracis vaccine - DynPort

Latest Information Update: 03 Apr 2008

Price : $50

At a glance

  • Originator DynPort Vaccine Company LLC
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 03 Apr 2008 Discontinued - Phase-I for Anthrax in USA (IM)
  • 23 Aug 2004 DynPort Vaccine Company LLC has been acquired by Computer Sciences Corporation
  • 12 Nov 2002 Phase-I clinical trials in Anthrax in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top